Global trends in the epidemiology and management of dyslipidemia
T Liu, D Zhao, Y Qi - Journal of clinical medicine, 2022 - mdpi.com
Dyslipidemia, especially a circulating non-optimal level of cholesterol, is one of the most
important risk factors for atherosclerotic cardiovascular disease (ASCVD), which accounts …
important risk factors for atherosclerotic cardiovascular disease (ASCVD), which accounts …
[HTML][HTML] Dyslipidemia management for primary prevention of cardiovascular events: Best in-clinic practices
N Thongtang, R Sukmawan, EJB Llanes… - Preventive Medicine …, 2022 - Elsevier
Dyslipidemia is a fundamental risk factor for cardiovascular diseases (CVDs) and can
worsen the prognosis, if unaddressed. Lipid guidelines are still evolving as dyslipidemia is …
worsen the prognosis, if unaddressed. Lipid guidelines are still evolving as dyslipidemia is …
[HTML][HTML] Predictors of outcomes of foot ulcers among individuals with type 2 diabetes mellitus in an outpatient foot clinic
RR Felipe, MT Plata-Que - Journal of the ASEAN Federation of …, 2021 - ncbi.nlm.nih.gov
Predictors of Outcomes of Foot Ulcers among Individuals with Type 2 Diabetes Mellitus in an
Outpatient Foot Clinic - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
Outpatient Foot Clinic - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
[HTML][HTML] Framework of Guidelines for Management of CKD in Asia
C Pollock, J Moon, P Gojaseni, CH Ching… - Kidney International …, 2024 - Elsevier
Methods For developing a recommendations framework for CKD in Asia, a 3-step process
was implemented. A meeting was conducted where key recommendations from several …
was implemented. A meeting was conducted where key recommendations from several …
Management of Dyslipidemia and Hypertension–Journey Mapping in the Philippines
AA Atilano, EJB Llanes, DID Ona, GE Brizuela - Acta Medica, 2022 - actamedica.org
Management of Dyslipidemia and Hypertension – Journey Mapping in the Philippines Page
1 307 © 2022 Acta Medica. Acta Medica 2022; 53(4): 307-316 DOI: 10.32552/2022.ActaMedica.796 …
1 307 © 2022 Acta Medica. Acta Medica 2022; 53(4): 307-316 DOI: 10.32552/2022.ActaMedica.796 …
[PDF][PDF] Faktor Resiko pada Pasien Dislipidemia
SRM Siregar, E Boy - Jurnal Implementa Husada, 2022 - scholar.archive.org
Dislipidemia adalah ketidakseimbangan lipid seperti kolesterol, kolesterol lipoprotein
densitas rendah (LDL-C), trigliserida, dan lipoprotein densitas tinggi (HDL). Data di …
densitas rendah (LDL-C), trigliserida, dan lipoprotein densitas tinggi (HDL). Data di …
The prevalence of metabolic syndrome among adult Filipinos with hypothyroidism: A retrospective cohort study
HHC Chiu, RB Larrazabal Jr… - Acta Medica …, 2023 - actamedicaphilippina.upm.edu.ph
The Prevalence of Metabolic Syndrome among Adult Filipinos with Hypothyroidism: A
Retrospective Cohort Study Page 1 The Prevalence of Metabolic Syndrome among Adult …
Retrospective Cohort Study Page 1 The Prevalence of Metabolic Syndrome among Adult …
[HTML][HTML] A Comparison of Statin Treatment Algorithms Based on the ACC/AHA and Philippine Guidelines for Primary Prevention of Dyslipidemia in Statin-Naive …
BP Maglinte, A Junia, J Robles - Journal of the ASEAN Federation …, 2022 - ncbi.nlm.nih.gov
Objectives This cross-sectional study evaluates the degree of agreement between the 2018
American College of Cardiology/American Heart Association (ACC/AHA2018) and 2020 …
American College of Cardiology/American Heart Association (ACC/AHA2018) and 2020 …
The efficacy and safety of Emblica officinalis aqueous fruit extract among adult patients with dyslipidemia: A systematic review and meta-analysis
LRT Acampado, HHC Chiu… - Acta Medica …, 2023 - actamedicaphilippina.upm.edu.ph
The Efficacy and Safety of Emblica officinalis Aqueous Fruit Extract among Adult Patients with
Dyslipidemia: A Systematic Review Page 1 The Efficacy and Safety of Emblica officinalis …
Dyslipidemia: A Systematic Review Page 1 The Efficacy and Safety of Emblica officinalis …
[PDF][PDF] Dyslipidemia 5
A MOA - PHA FORMULARY, 2023 - pha2024.netheadinfotech.net
▪ INDICATIONS AND DOSE FH or mixed dyslipidemia in patients who have not responded
adequately to:(1) other appropriate measures in combination with a Statin;(2) Statin and …
adequately to:(1) other appropriate measures in combination with a Statin;(2) Statin and …